{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T04:01:02Z","timestamp":1780977662400,"version":"3.54.1"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.msard.2026.107220","type":"journal-article","created":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:24:40Z","timestamp":1777595080000},"page":"107220","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Differential safety profiles of disease-modifying therapies in MS: Age- and sex-based analysis from a real-world cohort"],"prefix":"10.1016","volume":"111","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9184-1144","authenticated-orcid":false,"given":"Melike Cakan","family":"Ercan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elif","family":"Cakan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasemin","family":"Gumus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nazire P\u0131nar Acar","family":"Ozen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asl\u0131","family":"Tuncer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4272-1482","authenticated-orcid":false,"given":"Rana","family":"Karabudak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2026.107220_bib0001","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.msard.2017.12.003","article-title":"Predictors of hematological abnormalities in multiple sclerosis patients treated with fingolimod and dimethyl fumarate and impact of treatment switch on lymphocyte and leukocyte count","volume":"20","author":"Baharnoori","year":"2018","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2026.107220_bib36","doi-asserted-by":"crossref","unstructured":"Baiamonte, L., Enea, M., Vaccaro, M., Ragonese, P., Salemi, G., n.d.. Sex differences in multiple sclerosis treatment with disease modifying drugs: a step towards gender neurology. Mult Scler Relat Disord 2025 (105), 106869. doi:10.1016\/j.msard.2025.106869.","DOI":"10.1016\/j.msard.2025.106869"},{"issue":"3","key":"10.1016\/j.msard.2026.107220_bib0002","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1007\/s43440-025-00725-6","article-title":"Lymphopenia associated with sphingosine 1-phosphate receptor modulators (S1PRMs) in multiple sclerosis: analysis of European pharmacovigilance data","volume":"77","author":"Balzano","year":"2025","journal-title":"Pharmacol. Rep."},{"key":"10.1016\/j.msard.2026.107220_bib37","doi-asserted-by":"crossref","first-page":"103857","DOI":"10.1016\/j.msard.2022.103857","article-title":"Effects of disease-modifying treatments discontinuation in patients with relapsing-remitting multiple sclerosis: A 5 year prospective cohort study","volume":"63","author":"Bawand","year":"2022","journal-title":"Mult Scler Relat Disord"},{"issue":"2","key":"10.1016\/j.msard.2026.107220_bib0003","article-title":"Lymphocyte subtypes in relapsing-remitting multiple sclerosis patients treated with dimethyl fumarate","volume":"3","author":"Chaves","year":"2017","journal-title":"Mult. Scler. J. Exp. Transl. Clin."},{"key":"10.1016\/j.msard.2026.107220_bib0004","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s00508-024-02346-0","article-title":"Impact of age on the transmission of SARS-CoV-2 in healthcare workers","volume":"136","author":"Corral-Gudino","year":"2024","journal-title":"Wien. Klin. Wochenschr."},{"issue":"6","key":"10.1016\/j.msard.2026.107220_bib0005","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/s00415-025-13133-w","article-title":"Real-world observational study of infections in people treated with ocrelizumab for multiple sclerosis","volume":"272","author":"Davies","year":"2025","journal-title":"J. Neurol."},{"issue":"4","key":"10.1016\/j.msard.2026.107220_bib0006","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.vaccine.2012.11.041","article-title":"Cytomegalovirus-associated accumulation of late-differentiated CD4 T-cells correlates with poor humoral response to influenza vaccination","volume":"31","author":"Derhovanessian","year":"2013","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.msard.2026.107220_bib0007","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/cei.12700","article-title":"The ageing human B cell repertoire: a failure of selection?","volume":"183","author":"Dunn-Walters","year":"2015","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.msard.2026.107220_bib0008","article-title":"Effect of multiple sclerosis disease-modifying therapies on the real-world effectiveness of two doses of BBIBP-CorV (Sinopharm) vaccine","volume":"444","author":"Etemadifar","year":"2022","journal-title":"J. Neurol. Sci."},{"issue":"3","key":"10.1016\/j.msard.2026.107220_bib0009","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1111\/bph.12362","article-title":"Pharmacogenomics, pharmacokinetics and pharmacodynamics: interaction with biological differences between men and women","volume":"171","author":"Franconi","year":"2014","journal-title":"Br. J. Pharmacol."},{"issue":"3","key":"10.1016\/j.msard.2026.107220_bib0010","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1007\/s10875-010-9501-7","article-title":"Aging affects human B cell responses","volume":"31","author":"Frasca","year":"2011","journal-title":"J. Clin. Immunol."},{"key":"10.1016\/j.msard.2026.107220_bib0011","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.104251","article-title":"Longitudinal stability of JCV antibody index in Natalizumab treated people with multiple sclerosis","volume":"68","author":"Gaughan","year":"2022","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2026.107220_bib0012","doi-asserted-by":"crossref","DOI":"10.1177\/1756286420915005","article-title":"Safety and efficacy of delayed-release dimethyl fumarate in patients with relapsing-remitting multiple sclerosis: 9 years' follow-up of DEFINE, CONFIRM, and ENDORSE","volume":"13","author":"Gold","year":"2020","journal-title":"Ther. Adv. Neurol. Disord."},{"issue":"8","key":"10.1016\/j.msard.2026.107220_bib0013","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s11910-017-0771-9","article-title":"Immunosenescence: the role of aging in the predisposition to neuro-infectious complications arising from the treatment of multiple sclerosis","volume":"17","author":"Grebenciucova","year":"2017","journal-title":"Curr. Neurol. Neurosci. Rep."},{"issue":"3","key":"10.1016\/j.msard.2026.107220_bib0014","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0174005","article-title":"Stability and predictive value of anti-JCV antibody index in multiple sclerosis: a 6-year longitudinal study","volume":"12","author":"Hegen","year":"2017","journal-title":"PLoS. One"},{"issue":"6","key":"10.1016\/j.msard.2026.107220_bib0015","doi-asserted-by":"crossref","first-page":"3256","DOI":"10.1007\/s00415-024-12270-y","article-title":"Sex impacts treatment decisions in multiple sclerosis","volume":"271","author":"Hegen","year":"2024","journal-title":"J. Neurol."},{"issue":"11","key":"10.1016\/j.msard.2026.107220_bib0016","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1177\/1352458518771840","article-title":"It is time to conduct phase 3 clinical trials of sex hormones in MS - No","volume":"24","author":"Houtchens","year":"2018","journal-title":"Mult. Scler."},{"issue":"6","key":"10.1016\/j.msard.2026.107220_bib0017","doi-asserted-by":"crossref","first-page":"663","DOI":"10.3988\/jcn.2022.18.6.663","article-title":"Safety and temporal pattern of the lymphocyte count during fingolimod therapy in patients with multiple sclerosis: real-world Korean experience","volume":"18","author":"Huh","year":"2022","journal-title":"J. Clin. Neurol."},{"key":"10.1016\/j.msard.2026.107220_bib0018","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.19766","article-title":"Association between Anti-CD20 therapies and COVID-19 severity among patients with relapsing-remitting and progressive multiple sclerosis","volume":"6","author":"Januel","year":"2023","journal-title":"JAMa Netw. Open."},{"issue":"3","key":"10.1016\/j.msard.2026.107220_bib0019","first-page":"88","article-title":"Effects of fingolimod treatments on alanine transaminase and aspartate transaminase levels in patients with multiple sclerosis","volume":"12","author":"Joni","year":"2020","journal-title":"Int. J. Physiol. Pathophysiol. Pharmacol."},{"key":"10.1016\/j.msard.2026.107220_bib41","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1007\/s00415-018-8831-x","article-title":"A multicentRE observational analysiS of PErsistenCe to Treatment in the new multiple sclerosis era: the RESPECT study","volume":"265","author":"Lanzillo","year":"2018","journal-title":"J. of Neurol."},{"key":"10.1016\/j.msard.2026.107220_bib0020","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.3389\/fneur.2020.00818","article-title":"A comprehensive monitoring study on electrocardiographic assessments and cardiac events after fingolimod first dose\u2014possible predictors of cardiac outcomes","volume":"11","author":"Limmroth","year":"2020","journal-title":"Front. Neurol."},{"key":"10.1016\/j.msard.2026.107220_bib0021","article-title":"Dimethyl fumarate-associated lymphopenia: risk factors and clinical significance","volume":"1","author":"Longbrake","year":"2015","journal-title":"Mult. Scler. J. Exp. Transl. Clin."},{"key":"10.1016\/j.msard.2026.107220_bib0022","doi-asserted-by":"crossref","DOI":"10.1002\/brb3.804","article-title":"Gender differences in safety issues during Fingolimod therapy: evidence from a real-life relapsing Multiple Sclerosis cohort","volume":"7","author":"Manni","year":"2017","journal-title":"Brain Behav."},{"key":"10.1016\/j.msard.2026.107220_bib42","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0038661","article-title":"EDSS Change and Therapy Choice Independently Predict Treatment Discontinuation in Multiple Sclerosis and Clinically Isolated Syndrome","volume":"7","author":"Meyniel","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1016\/j.msard.2026.107220_bib0023","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1177\/1352458520948231","article-title":"Multiple sclerosis management during the COVID-19 pandemic","volume":"26","author":"Moss","year":"2020","journal-title":"Mult. Scler."},{"issue":"1","key":"10.1016\/j.msard.2026.107220_bib0024","article-title":"Risk factors for fingolimod-induced lymphopenia in multiple sclerosis","volume":"4","author":"Ohtani","year":"2018","journal-title":"Mult. Scler. J. Exp. Transl. Clin."},{"key":"10.1016\/j.msard.2026.107220_bib0025","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7365\/JHPOR.2024.1.5","article-title":"Is disease-modifying therapy use in multiple sclerosis a risk factor during the COVID-19 pandemic? A large cohort study","author":"Ozakbas","year":"2024","journal-title":"J. Health Policy Outcomes Res."},{"key":"10.1016\/j.msard.2026.107220_bib0026","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.104081","article-title":"Risk factors for development of lymphopenia in dimethyl fumarate-treated patients with multiple sclerosis","volume":"67","author":"Ravn","year":"2022","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2026.107220_bib0027","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.103669","article-title":"Early predictive risk factors for dimethyl fumarate-associated lymphopenia in patients with multiple sclerosis","volume":"59","author":"Sainz de la Maza","year":"2022","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"8","key":"10.1016\/j.msard.2026.107220_bib0028","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1177\/1352458515607651","article-title":"PML risk stratification using anti-JCV antibody index and L-selectin","volume":"22","author":"Schwab","year":"2016","journal-title":"Mult. Scler."},{"issue":"8","key":"10.1016\/j.msard.2026.107220_bib0029","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1007\/s40263-021-00810-3","article-title":"Predicting infection risk in multiple sclerosis patients treated with Ocrelizumab: a retrospective cohort study","volume":"35","author":"Seery","year":"2021","journal-title":"CNS Drugs"},{"key":"10.1016\/j.msard.2026.107220_bib0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.102968","article-title":"The outcome of a national MS-Covid-19 study: what the Turkish MS cohort reveals?","volume":"52","author":"\u015een","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2026.107220_bib0031","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2024.105830","article-title":"Safety of high efficacy therapies in older people with Multiple Sclerosis: a real-world evidence study","volume":"90","author":"Silva","year":"2024","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2026.107220_bib0032","article-title":"Updated results of the COVID-19 in MS global data sharing initiative","volume":"9","author":"Simpson-Yap","year":"2022","journal-title":"Neurol.\u00ae Neuroimmunol. Neuroinflam."},{"key":"10.1016\/j.msard.2026.107220_bib43","first-page":"14","article-title":"Predictors of treatment switching in the big multiple sclerosis data network","author":"Spelman","year":"2023","journal-title":"Front. Neurol."},{"issue":"2","key":"10.1016\/j.msard.2026.107220_bib0033","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","article-title":"Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria","volume":"17","author":"Thompson","year":"2018","journal-title":"Lancet Neurol."},{"issue":"11","key":"10.1016\/j.msard.2026.107220_bib0034","article-title":"Adverse effects of immunotherapies for multiple sclerosis: a network meta-analysis","volume":"11","author":"Tramacere","year":"2023","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.msard.2026.107220_bib0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.104369","article-title":"Disease-modifying therapies, outcomes, risk factors and severity of COVID-19 in multiple sclerosis: a MENACTRIMS registry based study","volume":"71","author":"Zeineddine","year":"2023","journal-title":"Mult. Scler. Relat. Disord."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034826002567?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034826002567?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T03:44:13Z","timestamp":1780976653000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034826002567"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":40,"alternative-id":["S2211034826002567"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2026.107220","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Differential safety profiles of disease-modifying therapies in MS: Age- and sex-based analysis from a real-world cohort","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2026.107220","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"107220"}}